Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow Conversion Efficiency
Drugs Made In America Acquisition Corp. Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a cash flow conversion efficiency ratio of -0.002x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-244.61K) by net assets ($137.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
Cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025. This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Drugs Made In America Acquisition Corp. for real-time trading data and today's change.
Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow Conversion Ratio Explained
Drugs Made In America Acquisition Corp. Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Drugs Made In America Acquisition Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition Corp. Ordinary Shares ranked by their cash flow conversion efficiency. Also see DMAA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Hopechart Iot Technology
SHG:688288
|
0.038x |
|
HomeStreet Inc
NASDAQ:HMST
|
-0.024x |
|
Bonduelle S.C.A.
PA:BON
|
0.324x |
|
Dishman Carbogen Amcis Limited
NSE:DCAL
|
0.046x |
|
Zhejiang Yaguang Technology Co. Ltd. A
SHG:603282
|
N/A |
|
Linhai Co Ltd
SHG:600099
|
0.428x |
|
Karmarts Public Company Limited
BK:KAMART
|
0.029x |
|
Sportking India Limited
NSE:SPORTKING
|
0.142x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025. Review how much free cash does Drugs Made In America Acquisition Corp. generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.64 Million | $-539.19K | -0.002x | -100.00% |
| 2024-12-31 | $-244.85 | $-172.26K | 703.553x | -- |
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.